Literature DB >> 17117592

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.

Changhai Ding1.   

Abstract

Vertex Pharmaceuticals Inc, in collaboration with Kissei Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17117592

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  19 in total

1.  Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor.

Authors:  Ching Li; Paul Beavis; Andrew C Palfreeman; Parisa Amjadi; Alan Kennedy; Fionula M Brennan
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

Review 2.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

3.  The as-yet unfulfilled promise of p38 MAPK inhibitors.

Authors:  Susan E Sweeney
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

Review 4.  Anti-inflammatory strategies in cartilage repair.

Authors:  Ying Zhang; Tyler Pizzute; Ming Pei
Journal:  Tissue Eng Part B Rev       Date:  2014-06-23       Impact factor: 6.389

5.  Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms.

Authors:  Nicole C Kleinstreuer; Jian Yang; Ellen L Berg; Thomas B Knudsen; Ann M Richard; Matthew T Martin; David M Reif; Richard S Judson; Mark Polokoff; David J Dix; Robert J Kavlock; Keith A Houck
Journal:  Nat Biotechnol       Date:  2014-05-18       Impact factor: 54.908

6.  Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.

Authors:  Philipp Guenthoer; Kerstin Fuchs; Gerald Reischl; Leticia Quintanilla-Martinez; Irene Gonzalez-Menendez; Stefan Laufer; Bernd J Pichler; Manfred Kneilling
Journal:  Inflammopharmacology       Date:  2019-04-29       Impact factor: 4.473

Review 7.  "Go upstream, young man": lessons learned from the p38 saga.

Authors:  D Hammaker; G S Firestein
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

8.  Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death.

Authors:  Jiong Zhao; Zhenyu Zhang; Yang Liao; Wei Du
Journal:  Am J Cancer Res       Date:  2014-01-15       Impact factor: 6.166

Review 9.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

10.  A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.

Authors:  K Mihara; C Almansa; R L Smeets; E E M G Loomans; J Dulos; P M F Vink; M Rooseboom; H Kreutzer; F Cavalcanti; A M Boots; R L Nelissen
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.